Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Caskey

Showing results (1-10 of 130) with videos related to

Pageof 13
Sort By:
Current Opinion in HIV and AIDS|November 26, 2019
Broadly neutralizing antibodies for the treatment and prevention of HIV infectionMarina Caskey
The Lancet. HIV|March 31, 2023
High volume subcutaneous delivery of long-acting HIV bNAbsMarina Caskey
The Lancet. HIV|March 20, 2019
Delivery of anti-HIV bNAbs by viral vectorsMarina Caskey
The Lancet. HIV|December 12, 2024
Potential for broadly neutralising antibodies as PrEPSarah Fidler, Marina Caskey
The Journal of Infectious Diseases|November 5, 2019
Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?Christian Gaebler, Marina Caskey
The Journal of Infectious Diseases|March 3, 2026
What's Hot in HIV in 2025-A Basic and Translational Science Review from IDWeek 2025Ana Rafaela Teixeira, Marina Caskey
Current Opinion in HIV and AIDS|April 27, 2018
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infectionYehuda Z Cohen, Marina Caskey
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?Marina Caskey, Daniel R Kuritzkes
The New England Journal of Medicine|December 14, 2016
Broadly Neutralizing Antibodies for HIV-1 Prevention or ImmunotherapyMarina Caskey, Florian Klein, Michel C Nussenzweig
Nature Medicine|April 3, 2019
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinicMarina Caskey, Florian Klein, Michel C Nussenzweig
Pageof 13

Showing results (1-10 of 130) with videos related to

Sort By:
Pageof 13
Current Opinion in HIV and AIDS|November 26, 2019
Broadly neutralizing antibodies for the treatment and prevention of HIV infectionMarina Caskey
The Lancet. HIV|March 31, 2023
High volume subcutaneous delivery of long-acting HIV bNAbsMarina Caskey
The Lancet. HIV|March 20, 2019
Delivery of anti-HIV bNAbs by viral vectorsMarina Caskey
The Lancet. HIV|December 12, 2024
Potential for broadly neutralising antibodies as PrEPSarah Fidler, Marina Caskey
The Journal of Infectious Diseases|November 5, 2019
Broadly Neutralizing Antihuman Immunodeficiency Virus Antibodies in Infants: Promising New Tools for Prevention of Mother-to-Child Transmission?Christian Gaebler, Marina Caskey
The Journal of Infectious Diseases|March 3, 2026
What's Hot in HIV in 2025-A Basic and Translational Science Review from IDWeek 2025Ana Rafaela Teixeira, Marina Caskey
Current Opinion in HIV and AIDS|April 27, 2018
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infectionYehuda Z Cohen, Marina Caskey
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 21, 2022
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?Marina Caskey, Daniel R Kuritzkes
The New England Journal of Medicine|December 14, 2016
Broadly Neutralizing Antibodies for HIV-1 Prevention or ImmunotherapyMarina Caskey, Florian Klein, Michel C Nussenzweig
Nature Medicine|April 3, 2019
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinicMarina Caskey, Florian Klein, Michel C Nussenzweig
Pageof 13